Research ArticleNuclear Oncology
Pharmacokinetic Modeling and Absorbed Dose Estimation for Chimeric Anti-CEA Antibody in Humans
Tamara L. Odom-Maryon, Lawrence E. Williams, Akiko Chai, George Lopatin, An Liu, Jeffrey Y.C. Wong, Jeffrey Chou, Kenneth G. Clarke and Andrew A. Raubitschek
Journal of Nuclear Medicine December 1997, 38 (12) 1959-1966;
Tamara L. Odom-Maryon
Lawrence E. Williams
Akiko Chai
George Lopatin
An Liu
Jeffrey Y.C. Wong
Jeffrey Chou
Kenneth G. Clarke
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Pharmacokinetic Modeling and Absorbed Dose Estimation for Chimeric Anti-CEA Antibody in Humans
Tamara L. Odom-Maryon, Lawrence E. Williams, Akiko Chai, George Lopatin, An Liu, Jeffrey Y.C. Wong, Jeffrey Chou, Kenneth G. Clarke, Andrew A. Raubitschek
Journal of Nuclear Medicine Dec 1997, 38 (12) 1959-1966;
Pharmacokinetic Modeling and Absorbed Dose Estimation for Chimeric Anti-CEA Antibody in Humans
Tamara L. Odom-Maryon, Lawrence E. Williams, Akiko Chai, George Lopatin, An Liu, Jeffrey Y.C. Wong, Jeffrey Chou, Kenneth G. Clarke, Andrew A. Raubitschek
Journal of Nuclear Medicine Dec 1997, 38 (12) 1959-1966;
Jump to section
Related Articles
- No related articles found.
Cited By...
- A Phase I Study of a Combination of Yttrium-90-Labeled Anti-Carcinoembryonic Antigen (CEA) Antibody and Gemcitabine in Patients with CEA-Producing Advanced Malignancies
- Parametric Images of Antibody Pharmacokinetics Based on Serial Quantitative Whole-Body Imaging and Blood Sampling
- Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer
- A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer
- A Phase I Radioimmunotherapy Trial Evaluating 90Yttrium-labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies